Press release
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Primary Biliary Cirrhosis - Drug Pipeline Landscape
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline Landscape here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022
Researcher experts consider it as an autoimmune disease in which the body turns against its own cells and the exact cause is unknown. Researchers believe this autoimmune response may be triggered by environmental and genetic factors.
Primary Biliary Cirrhosis symptoms included dry eyes and mouth, spleen swelling, joint pain, buildup of fluid in the abdomen, jaundice, fatigue and itchy skin.
Blood tests including liver test, antibody test and cholesterol test may be used to diagnose primary biliary cirrhosis. Imaging tests looking at the liver and bile ducts may include fibroscan, ultrasound, MRCP and magnetic resonance elastopraphy.
Treatment of PBC include treating the disease with medications like ursodeoxycholic acid, obeticholic acid symptoms, fibrates and budesonide. Treating the symptoms like fatigue dry eyes and mouth may also alleviate the disease condition.
Request sample copy of this research study: https://www.globalinsightservices.com/request-sample/GIS31039/
Report Highlights
Global Insight Service's, Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2022 report provides an overview of the Primary Biliary Cirrhosis pipeline drugs. This report covers detailed insights on Primary Biliary Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Primary Biliary Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Some of the key players involved in development of Primary Biliary Cirrhosis therapeutics are :
• Albireo
• Calliditas Therapeutics AB
• CAMP4 Therapeutics Corp
• Cara Therapeutics, Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• COUR Pharmaceutical Development Company, Inc.
• CymaBay Therapeutics, Inc.
• Dr. Falk Pharma GmbH
• Escient Pharmaceuticals, Inc
• Future Medicine Co Ltd
• Gannex Pharma Co., Ltd.
• Genfit
• GentiBio Inc
• GlaxoSmithKline
• Hanmi Pharmaceuticals Co Ltd
Purchase your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31039/
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022 here
News-ID: 2785028 • Views: …
More Releases from Global Insight Services
Glp-1 Agonist Market To Surge From $53 BN To $264.9 BN By 2034 At 17.5% Cagr. Ke …
Market Overview
GLP-1 Agonist Market is rapidly evolving as the demand for advanced diabetes and obesity treatments continues to rise globally. These drugs, known as glucagon-like peptide-1 receptor agonists, help improve insulin secretion, reduce glucagon levels, and enhance satiety-making them a powerful solution for type 2 diabetes and weight management. With diabetes and obesity reaching unprecedented levels, the GLP-1 Agonist Market stands at the forefront of therapeutic innovation. Growing patient awareness,…
Financial Risk Management Software Market To Grow From $24.5 BN To $47.8 BN By 2 …
Market Overview
Financial Risk Management Software Market is evolving rapidly as financial institutions and enterprises navigate increasingly complex global uncertainties. With tightening regulations and growing exposure to market volatility, organizations are turning toward advanced digital solutions that help identify, assess, and mitigate financial risks in real time. The Financial Risk Management Software Market integrates AI, machine learning, predictive analytics, and cloud technologies to enhance credit, liquidity, operational, and market risk insights.…
Esg Risk Management Market To Rise From $268.8 MN To $1,032.2 MN By 2034 At 14.4 …
Market Overview
ESG Risk Management Market is gaining significant momentum as businesses increasingly prioritize sustainability and ethical governance in their operations. Valued at $268.8 million in 2024, the market is projected to surge to $1,032.2 million by 2034, growing at a CAGR of 14.4%. The ESG Risk Management Market encompasses technologies and services designed to identify, monitor, and mitigate environmental, social, and governance risks, ensuring businesses operate responsibly while complying with…
Enterprise Firewall Market To Grow From $15 BN (2024) To $40.3 BN (2034) At 10.4 …
Market Overview
Enterprise Firewall Market is witnessing substantial growth as organizations worldwide prioritize safeguarding their digital infrastructure from sophisticated cyber threats. Valued at $15 billion in 2024, the market is projected to reach $40.3 billion by 2034, expanding at a CAGR of 10.4%. The Enterprise Firewall Market encompasses solutions designed to secure enterprise networks by monitoring, filtering, and blocking unauthorized access while ensuring uninterrupted business operations. With the surge in cyberattacks,…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
